Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular
function and recalcitrant macular edema associated with retinal vein occlusion following
treatment with 2 or more prior intravitreal anti-VEGF drug injections.